Marcie Glicksman, PhD
Marcie Glicksman, Ph.D. is the Chief Scientific Officer at ORIG3N. ORIG3N combines genetics and regenerative medicine by leading the development of allogeneic, iPSC (induced pluripotent stem cell)-derived cell therapies by leveraging the world’s largest, uniformly consented, HLA-matched cell bank. Dr. Glicksman has over 75 publications and 12 issued patents. Dr. Glicksman has been in the field of drug discovery for more than 20 years. She worked in the bio-pharmaceutical industry for 13 years and then was recruited to join the faculty for ten years at Harvard Medical School and Brigham and Women’s Hospital and Co-Directed the Laboratory for Drug Discovery in Neurodegeneration (LDDN). While at LDDN, 8 start-up companies were spun out. In her career, she has led multiple advanced therapeutic programs including drug candidates that were tested in the clinic. She is on the science advisory board for the Alzheimer’s Drug Discovery Foundation (ADDF) and reviews grants for NIH, Department of Defense, the Michael J Fox Foundation, Weston Brain Institute, and the Francis Collins Scholar Program. Dr. Glicksman received a bachelor’s degree from Brown University and a Ph.D. degree in Neuroscience from Washington University.